Body Part, Organ, or Organ Component
Aligos Therapeutics’ HERALD Study Shows Promising MASH Treatment Results, Yet Fails to Impress Investors
Aligos Therapeutics, HERALD study, MASH treatment, ALG-055009, liver fat reduction, Phase 2a results, investor reaction.
AOA’s ‘Eye Deserve More’ Campaign Highlights the Unmatched Capabilities of the Human Eye
American Optometric Association, Eye Deserve More, The Eye, Human Eye, Eye Health, Comprehensive Eye Care, Digital Eye Strain, Vision Loss, Optometry
ImmunityBio Trims Workforce Despite Recent FDA Approval for Anktiva
ImmunityBio, Anktiva, FDA approval, layoffs, financial challenges, bladder cancer treatment
Novartis and Versant Ventures Launch Borealis Biosciences to Develop RNA Medicines for Kidney Diseases
Borealis Biosciences, Novartis, Versant Ventures, RNA medicines, kidney diseases, xRNA technology, biotechnology, startup, kidney research, RNA therapeutics.
Novartis and Versant Invest $150M in Kidney Biotech Borealis to Replicate Chinook’s Success
Novartis, Versant, Borealis, kidney biotech, $150M investment, Chinook Therapeutics, chronic kidney disease, biotech funding
Revolutionary AI and Brain Implants Restore ALS Patient’s Voice
ALS, brain-computer interface, AI, speech restoration, brain implants, medical breakthrough
Aldeyra’s Reproxalap Demonstrates Efficacy in Reducing Eye Discomfort in New Phase 3 Study
Aldeyra Therapeutics, Reproxalap, Phase 3 Study, Eye Discomfort, Dry Eye Disease, FDA Rejection
SandboxAQ and Mayo Clinic Partner to Revolutionize Cardiac Diagnostics with AI-Powered Magnetocardiography
SandboxAQ, Mayo Clinic, AI-powered magnetocardiography, cardiac diagnostics, CardiAQ, medical imaging technology, quantum sensors, large quantitative models
FDA Approves Servier’s Brain Cancer Drug, Triggering $1 Billion Payout for Agios
FDA approval, Servier, brain cancer drug, Voranigo, Agios Pharmaceuticals, IDH1 and IDH2 mutations, blood-brain barrier, cancer metabolism, royalty payments
NGM Bio Secures $122 Million in Funding After Going Private
NGM Bio, funding, private, Column Group, pipeline, orphan diseases